top of page
MTX-101

MTX-101

Preparing for IND-enabling studies

​

Our lead program is a small molecule injectable therapy being developed for cardiac regeneration following myocardial infarction.

​

Its goal is to activate regenerative processes in the injured heart.

THE MECHANISM

MTX-101 targets succinate dehydrogenase (SDH), a mitochondrial enzyme, to shift cardiac metabolism toward a regenerative state. The approach explores how metabolic reprogramming can support regeneration of injured heart tissue.

​

PRECLINICAL EVIDENCE

Research supporting the approach has demonstrated cardiomyocyte proliferation in adult mice and pigs, and in human cardiomyocytes.

In mouse models, studies have also shown restoration of cardiac structure and function, with revascularization and reduced fibrosis.

​

THE DEVELOPMENT GOAL

​We are advancing a small molecule injectable therapy for cardiac regeneration following myocardial infarction. MTX-101 is a first-in-class product candidate preparing for IND-enabling studies. Our goal is to translate the underlying biology into a therapy that can help people recovering from a heart attack.

© 2026 Mount Therapeutics, Inc. · La Jolla, California

bottom of page